GW Pharma aiming for FDA approval for CBD drug this year, again
British cannabis company GW Pharmaceuticals is hoping the U.S. Food and Drug Administration will sign off on its CBD-based epilepsy treatment, Epidiolex, as soon as this year. According to The Washington Post, GW is hoping to get the green light from the FDA to classify Epidiolex as a prescription drug,Continue Reading


